441 related articles for article (PubMed ID: 21074634)
21. Present drug-likeness filters in medicinal chemistry during the hit and lead optimization process: how far can they be simplified?
Mignani S; Rodrigues J; Tomas H; Jalal R; Singh PP; Majoral JP; Vishwakarma RA
Drug Discov Today; 2018 Mar; 23(3):605-615. PubMed ID: 29330127
[TBL] [Abstract][Full Text] [Related]
22. A new paradigm for improving oral absorption of drugs in discovery: role of physicochemical properties, different excipients and the pharmaceutical scientist.
Wilson AG; Nouraldeen A; Gopinathan S
Future Med Chem; 2010 Jan; 2(1):1-5. PubMed ID: 21426039
[No Abstract] [Full Text] [Related]
23. Is chemical synthetic accessibility computationally predictable for drug and lead-like molecules? A comparative assessment between medicinal and computational chemists.
Bonnet P
Eur J Med Chem; 2012 Aug; 54():679-89. PubMed ID: 22749644
[TBL] [Abstract][Full Text] [Related]
24. The impact of physicochemical and molecular properties in drug design: navigation in the "drug-like" chemical space.
Vallianatou T; Giaginis C; Tsantili-Kakoulidou A
Adv Exp Med Biol; 2015; 822():187-94. PubMed ID: 25416989
[TBL] [Abstract][Full Text] [Related]
25. In silico prediction of ADME properties: are we making progress?
Beresford AP; Segall M; Tarbit MH
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):36-42. PubMed ID: 14982146
[TBL] [Abstract][Full Text] [Related]
26. Accelerating the drug-discovery process: new tools and technologies available to medicinal chemists.
Raveglia LF; Giardina GA
Future Med Chem; 2009 Sep; 1(6):1019-23. PubMed ID: 21425990
[No Abstract] [Full Text] [Related]
27. Oral delivery of G protein-coupled receptor modulators: an explanation for the observed class difference.
Beaumont K; Schmid E; Smith DA
Bioorg Med Chem Lett; 2005 Aug; 15(16):3658-64. PubMed ID: 15982884
[TBL] [Abstract][Full Text] [Related]
28. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
Dahan A; Hoffman A
J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
[TBL] [Abstract][Full Text] [Related]
29. Physicochemical descriptors of aromatic character and their use in drug discovery.
Ritchie TJ; Macdonald SJ
J Med Chem; 2014 Sep; 57(17):7206-15. PubMed ID: 24856517
[TBL] [Abstract][Full Text] [Related]
30. Precompetitive preclinical ADME/Tox data: set it free on the web to facilitate computational model building and assist drug development.
Ekins S; Williams AJ
Lab Chip; 2010 Jan; 10(1):13-22. PubMed ID: 20024044
[TBL] [Abstract][Full Text] [Related]
31. Genetic algorithm-optimized QSPR models for bioavailability, protein binding, and urinary excretion.
Wang J; Krudy G; Xie XQ; Wu C; Holland G
J Chem Inf Model; 2006; 46(6):2674-83. PubMed ID: 17125207
[TBL] [Abstract][Full Text] [Related]
32. Handing over the baton: connecting medicinal chemistry with process R&D.
Federsel HJ
Drug News Perspect; 2008 May; 21(4):193-9. PubMed ID: 18560618
[TBL] [Abstract][Full Text] [Related]
33. Going further than Lipinski's rule in drug design.
Walters WP
Expert Opin Drug Discov; 2012 Feb; 7(2):99-107. PubMed ID: 22468912
[TBL] [Abstract][Full Text] [Related]
34. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
O'Driscoll CM; Griffin BT
Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
[TBL] [Abstract][Full Text] [Related]
35. Fragments, network biology and designing multiple ligands.
Morphy R; Rankovic Z
Drug Discov Today; 2007 Feb; 12(3-4):156-60. PubMed ID: 17275736
[TBL] [Abstract][Full Text] [Related]
36. Lipophilicity--methods of determination and its role in medicinal chemistry.
Rutkowska E; Pajak K; Jóźwiak K
Acta Pol Pharm; 2013; 70(1):3-18. PubMed ID: 23610954
[TBL] [Abstract][Full Text] [Related]
37. Expediting drug discovery: recent advances in fast medicinal chemistry--optimization of hits and leads.
Edwards PJ; Allart B; Andrews MJ; Clase JA; Menet C
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):425-44. PubMed ID: 16889227
[TBL] [Abstract][Full Text] [Related]
38. Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery.
Wuelfing WP; El Marrouni A; Lipert MP; Daublain P; Kesisoglou F; Converso A; Templeton AC
J Med Chem; 2022 Feb; 65(3):1685-1694. PubMed ID: 35060378
[TBL] [Abstract][Full Text] [Related]
39. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective.
Zhao H
Drug Discov Today; 2007 Feb; 12(3-4):149-55. PubMed ID: 17275735
[TBL] [Abstract][Full Text] [Related]
40. Lead optimization strategies as part of a drug metabolism environment.
Korfmacher WA
Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
